The Checkpoint Inhibitor Refractory Cancer market is witnessing robust growth driven by innovation in immunotherapy and rising incidences of cancer patients resistant to first-line checkpoint inhibitors. Increasing adoption of combination therapies and personalized medicine approaches shape the evolving industry dynamics, making it a critical focus area for pharmaceutical companies and biotech...